Daljit Singh Aurora sold $432k of NMRA
See Remarks at Neumora Therapeutics, Inc.. 277,773 shares at an average of $1.55, traded Aug 17, 2026, filed Aug 19, 2026.
Score components
- +15RoleOfficer
- +17Trade size$432k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-26-000362, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | MOption exercise Common Stock | +40,890 | $0.72 | $29k | 123,660 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Common Stock | +15,355 | $0.72 | $11k | 139,015 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Common Stock | +1,424 | $0.72 | $1,025 | 140,439 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Common Stock | +1 | $0.72 | $1 | 140,440 | Aug 19, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock | -57,670 | $1.51 | $87k | 82,770 | Aug 19, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock | -34,020 | $1.49 | $51k | 48,750 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Common Stockindirect: See footnote | +25,279 | $0.72 | $18k | 25,279 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Common Stockindirect: See footnote | +29,737 | $0.72 | $21k | 55,016 | Aug 19, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stockindirect: See footnote | -55,016 | $1.50 | $83k | 0 | Aug 19, 2026 |
| Aug 18, 2026 | MOption exercise Common Stock | +34,162 | $0.72 | $25k | 82,912 | Aug 19, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stock | -34,162 | $1.58 | $54k | 48,750 | Aug 19, 2026 |
| Aug 18, 2026 | MOption exercise Common Stockindirect: See footnote | +34,987 | $0.72 | $25k | 34,987 | Aug 19, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stockindirect: See footnote | -34,987 | $1.59 | $55k | 0 | Aug 19, 2026 |
| Aug 19, 2026 | MOption exercise Common Stock | +13,268 | $0.72 | $9,553 | 62,018 | Aug 19, 2026 |
| Aug 19, 2026 | MOption exercise Common Stock | +17,732 | $0.72 | $13k | 79,750 | Aug 19, 2026 |
| Aug 19, 2026 | SOpen-market sale Common Stock | -31,000 | $1.65 | $51k | 48,750 | Aug 19, 2026 |
| Aug 19, 2026 | MOption exercise Common Stockindirect: See footnote | +30,918 | $0.72 | $22k | 30,918 | Aug 19, 2026 |
| Aug 19, 2026 | SOpen-market sale Common Stockindirect: See footnote | -30,918 | $1.65 | $51k | 0 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -40,890 | $0.00 | $0 | 0 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -15,355 | $0.00 | $0 | 192,546 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -1,424 | $0.00 | $0 | 70,797 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -1 | $0.00 | $0 | 999,999 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivativeindirect: See footnote | -25,279 | $0.00 | $0 | 110,931 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivativeindirect: See footnote | -29,737 | $0.00 | $0 | 0 | Aug 19, 2026 |
| Aug 18, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -34,162 | $0.00 | $0 | 36,635 | Aug 19, 2026 |
| Aug 18, 2026 | MOption exercise Stock Option (Right to Buy)derivativeindirect: See footnote | -34,987 | $0.00 | $0 | 75,944 | Aug 19, 2026 |
| Aug 19, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -13,268 | $0.00 | $0 | 23,367 | Aug 19, 2026 |
| Aug 19, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -17,732 | $0.00 | $0 | 177,268 | Aug 19, 2026 |
| Aug 19, 2026 | MOption exercise Stock Option (Right to Buy)derivativeindirect: See footnote | -30,918 | $0.00 | $0 | 45,026 | Aug 19, 2026 |
Related signals
Other insiders at Neumora Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | NMRAsell Neumora Therapeutics, Inc. | Daljit Singh Aurora See Remarks | $270k 176,060 shares | -151% | |
| 30Weak | Neumora Therapeutics, Inc. | Daljit Singh Aurora See Remarks | $22k 6,165 shares | -7% | |
| 36Weak | Neumora Therapeutics, Inc. | Paul L Berns See Remarks | $34k 9,819 shares | -0% | |
| 10Weak | Neumora Therapeutics, Inc. | Michael Lee Milligan See Remarks | $5,119 1,436 shares | -6% | |
| 35Weak | Neumora Therapeutics, Inc. | Joshua Pinto President | $21k 5,967 shares | -9% | |
| 29Weak | Neumora Therapeutics, Inc. | Daljit Singh Aurora See Remarks | $307k 114,703 shares | -100% | |
| 61Notable | Neumora Therapeutics, Inc. | ARCH Venture Partners X, LLC owner | $5.0M 1,915,700 shares | +46% | |
| 61Notable | Neumora Therapeutics, Inc. | ARCH Venture Partners XII, LLC owner | $5.0M 1,915,700 shares | +46% | |
| 69Notable | Neumora Therapeutics, Inc. | Kristina Burow director, owner | $5.0M 1,915,700 shares | +46% | |
| 3Weak | Neumora Therapeutics, Inc. | Daljit Singh Aurora Chief Strategy Officer | $14k 8,565 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.